A method for manufacturing a steel sheet having a yield strength YS of more than 1000 MPa, a tensile strength TS of more than 1150 MPa and a total elongation E of more than 8%, comprising the steps of: —preparing a steel sheet through rolling from a steel containing in percent by weight 0.19% to 0.22% C, 2% to 2.6% Mn, 1.45% to 1.55% Si, 0.15% to 0.4% Cr, less than 0.020% P, less than 0.05% S, less than 0.08% N, 0.015% to 0.070% Al, the reminder being Fe and unavoidable impurities, —soaking the sheet at an annealing temperature TA between 860° C. and 890° C. for a time between 100 s and 210 s, cooling the sheet to a quenching temperature QT between 220° C. and 330° C., from a temperature TC not less than 500° C. at a cooling speed not less than 15° C./s, heating the steel sheet during a time between 115 s and 240 s up to a first overaging temperature TOA1 higher than 380° C., then heating the sheet during a time between 300 s and 610 s up to a second overaging temperature TOA2 between 420° and 450° C., cooling the steel sheet to a temperature less than 100° C. at a cooling speed less than 5° C./s. The structure of the steel containing more than 80% of tempered martensite, more than 5% of retained austenite, less than 5% of ferrite, less than 5% of bainite and less than 6% of fresh martensite.

Disclosed are a microneedle patch including a first hydrogel layer containing a mussel adhesive protein and hyaluronic acid, and a second hydrogel layer containing silk fibroin, and a preparation method thereof. The microneedle patch according to the present disclosure has excellent tissue adhesion, biocompatibility, and biodegradability, and is used for transdermal drug delivery to promote wound regeneration.

The present invention relates to a transdermal therapeutic system for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; B) a rivastigmine-containing layer comprising at least one acrylic polymer; and C) a skin contact layer comprising at least one styrene-isoprene-styrene block copolymer and at least one tackifier.

The disclosure provides new medical device and manufacturing methods as well as chemicals that enhance delivery of pharmaceuticals from a transdermal patch, where the patch may include a film, adhesive, emulsifier, tackifier, or hydrogel.

Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

The disclosure provides complexes for desired usage as as chemical groups that enhance delivery of moieties from a buccal setting or from a transdermal patch, where the CBD unexepectely enhances the transmission and availability of actives.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.

The present invention concerns a transdermal delivery system (TDS) comprising at least one active ingredient, wherein the active ingredient is in a non-aqueous matrix, and wherein the non-aqueous matrix has a reduced moisture content. Furthermore, the present invention concerns a method for the production of the TDS in accordance with the invention, as well as the use of the TDS in accordance with the invention.

A percutaneous absorption agent delivery device with: a solvent-impermeable cover film that has a first layer and a second layer, which are integrally continuous via a first fold and are superimposed, a non-seal region and a seal region are formed between the first layer and the second layer, the non-seal region disposed along the first fold, the seal region to surround the outer peripheral section of the non-seal region except for the section along the first fold, and an endless cut portion forming the non-seal region formed in the cover film; a percutaneous absorption agent carrying member is disposed in the non-seal region between the first layer and the second layer, and fixed to the cover film on the inner side of the cut portion; and an adhesive sheet that is detachably affixed to the outer surface of the cover film.

A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (SIS) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.